19th October 2015
The Magstim Company announce the appointment of Dr Linda L. Carpenter, M.D as Chief Medical Advisor
The innovative and award winning medical device manufacturer, The Magstim Company Ltd, has announced the appointment of Dr Linda L. Carpenter, M.D as Chief Medical Advisor, with immediate effect.
Dr Carpenter will draw on experience from her roles as Professor of Psychiatry & Human Behaviour (Brown University, Rhode Island) and Chief of the Mood Disorder Program at Butler Hospital (Providence, Rhode Island), in order to provide clinician centric insight into the current and future developments of Magstim’s repetitive Transcranial Magnetic Stimulation (rTMS) technology.
Magstim received FDA 510(k) clearance to market its Magstim Rapid2 Therapy System for the treatment of drug resistant Major Depressive Disorder in the United States in May 2015. This clearance means Magstim can now significantly increase patient and clinician access to its latest rTMS products across the United States.
Speaking of her appointment, Dr Carpenter commented:
“I am very pleased to be taking on the role of Chief Medical Advisor for Magstim. The company is full of talented people with the very highest level of expertise in brain stimulation, and an exceptional dedication to customer service.”
“My extensive experience as a rTMS researcher and psychiatrist delivering clinical TMS therapy to patients with Major Depression for the past 6 years, will be of benefit when introducing this exciting new treatment into mental health care settings. I look forward to providing Magstim with specialist medical guidance in support of the successful introduction of its Rapid2 Therapy System in the US.”
CEO of Magstim, Mr Robin Davies explains:
“Professor Carpenter’s appointment as a practicing clinical psychiatrist brings a wealth of knowledge and experience to Magstim. Her insight into the treatment of Major Depressive Disorder with rTMS is an invaluable asset for Magstim in the development of innovative solutions for clinicians and patients alike.”
Magstim is the pioneer of TMS technology, having established a reputation for developing leading medical devices in the research field for over 25 years. The founding research team behind TMS (Sheffield University, 1985) is actively involved with the company, ensuring that its technology meets and exceeds the needs of today’s researcher and clinician. The company is now committed to build on its experience by bringing its knowledge to the US clinical market.